RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.

RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.

Influenza viruses (IVs) tend to rapidly develop resistance to virus-directed vaccines and common antivirals targeting pathogen determinants, but novel host-directed approaches might preclude resistance development. To identify the most promising cellular targets for a host-directed approach against...

Full description

Bibliographic Details
Main Authors: Markus Lesch, Madlen Luckner, Michael Meyer, Friderike Weege, Isabella Gravenstein, Martin Raftery, Christian Sieben, Laura Martin-Sancho, Aki Imai-Matsushima, Robert-William Welke, Rebecca Frise, Wendy Barclay, Günther Schönrich, Andreas Herrmann, Thomas F Meyer, Alexander Karlas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-03-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC6422253?pdf=render

Internet

http://europepmc.org/articles/PMC6422253?pdf=render

Similar Items